Compare AST SpaceMobile Inc (ASTS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs Johnson & Johnson — how do they compare? AST SpaceMobile Inc trades at $71.98 (market cap $20.54B), while Johnson & Johnson trades at $259.77 (market cap $630.94B). The key difference: Johnson & Johnson is far larger — about 30.7× AST SpaceMobile Inc's market cap, and Johnson & Johnson pays a 2.05% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| ASTS | JNJ | |
|---|---|---|
Market Cap | $20.54B | $630.94B |
Sector | Media | Health |
52-Week High | $133.09 | $267.24 |
52-Week Low | $36.91 | $172.78 |
Enterprise Value | $21.25B | $659.21B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
